Abstract
Ergot-derived dopamine receptor agonists, especially pergolide and cabergoline, have been associated with an increased risk of valvular heart disease in patients treated for Parkinson’s disease. Cabergoline at lower doses than those employed in Parkinson’s disease is widely used in patients with prolactinomas, because of its high efficacy and tolerability; however, its safety with regard to cardiac valve disease is unknown. In order to assess the prevalence of cardiac valve regurgitation in patients with prolactinomas treated with long-term cabergoline, we performed a prospective and multicentric study including four university centers in the province of Quebec. A transthoracic echocardiogram was performed in 70 patients with prolactinomas treated with cabergoline for at least 1 year (duration of treatment, 55 ± 22 months; cumulative dose 282 ± 271 mg, mean ± SD) and 70 control subjects matched for age and sex. Valvular regurgitation was graded according to the American Society of Echocardiography recommendations as mild, moderate, or severe. Moderate valvular regurgitation was found in four patients (5.7%) and five control subjects (7.1%) (P = 0.73). No patient had severe valvular regurgitation. There was no correlation between the presence of significant heart-valve regurgitation and cabergoline cumulative dose, duration of cabergoline treatment, prior use of bromocriptine, age, adenoma size, or prolactin levels. Our results show that low doses of cabergoline seem to be a safe treatment of hyperprolactinemic patients. However, in patients with prolonged cabergoline treatment, we suggest that echocardiographic surveillance may be warranted.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Van CG, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van ZM et al (2004) Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet 363:1179–1183. doi:10.1016/S0140-6736(04)15945-X
Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29–38. doi:10.1056/NEJMoa062222
Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 356:39–46. doi:10.1056/NEJMoa054830
Colao A, Di SA, Cappabianca P, Di SC, Pivonello R, Lombardi G (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023–2033. doi:10.1056/NEJMoa022657
Schlechte JA (2007) Long-term management of prolactinomas. J Clin Endocrinol Metab 92:2861–2865. doi:10.1210/jc.2007-0836
Serri O, Chik CL, Ur E, Ezzat S (2003) Diagnosis and management of hyperprolactinemia. CMAJ 169:575–581
Sherlock M, Steeds R, Toogood AA (2007) Dopamine agonist therapy and cardiac valve dysfunction. Clin Endocrinol (Oxf) 67:643–644. doi:10.1111/j.1365-2265.2007.02974.x
Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA et al (2003) Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16:777–802. doi:10.1016/S0894-7317(03)00335-3
Lancellotti P, Livadariu E, Markov M, Daly A, Burlacu MC, Betea D, Pierard L, Beckers A (2008) Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 159:1–5
Bogazzi F, Buralli S, Manetti L, Raffaelli V, Cigni T, Lombardi M, Boresi F, Taddei S, Salvetti A, Martino E (2008) Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract. doi:10.1111/j.1742-1241.2008.01779.x
Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD et al (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65:265–273. doi:10.1111/j.1365-2265.2006.02562.x
Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G (2006) The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 64:366–370
Verhelst J, Abs R, Maiter D, Van den BA, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518–2522. doi:10.1210/jc.84.7.2518
Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27:485–534. doi:10.1210/er.2005-9998
Shimon I, Benbassat C, Hadani M (2007) Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol 156:225–231. doi:10.1530/EJE-06-0646
Pastor P, Tolosa E (2003) Cabergoline in the treatment of Parkinson’s disease. Neurologia 18:202–209
Antonini A, Poewe W (2007) Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol 6:826–829. doi:10.1016/S1474-4422(07)70218-1
Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ et al (2000) Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102:2836–2841
Acknowledgments
We acknowledge the contribution of the following endocrinologists who recruited patients for the study: Georges Bahsali, Catherine Beauregard, Isabelle Bourdeau, Hortensia Mircescu, and Nicole Van Rossum, Montreal, Quebec, Canada
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vallette, S., Serri, K., Rivera, J. et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 12, 153–157 (2009). https://doi.org/10.1007/s11102-008-0134-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-008-0134-2